Cancer and Leukemia Group B
[pic]
Date: October 10, 2013
To: Experimental Therapeutics Committee
From: Charles Erlichman, MD and Gary Schwartz, MD
Re: Experimental Therapeutics Committee Meeting
Friday, November 8, 2013
Time: 8AM-11AM CST
Location: TBD (per agenda for the Alliance mtg)
Call In Information: 800-501-8979 / 8087368
AGENDA
1. Status update on activated current trials: (appx. 60 min) Horvath
|a. |A091104 |Phase II MK-2206 in Patients with progressive recurrent/metastatic Adenoid Cystic |A. Ho |
| | |Carcinoma | |
|b. |A091103 |Phase 2 Study of Angiopoitein -1 and -2 peptibody AMG386 for the Treatment of |S. D'Angelo |
| | |Angiosarcoma | |
|c. |A091102 |Phase II study of MLN8237 in advanced metastatic Sarcoma |M. Dickson |
|d. |A091101 |TPF Induction chemotherapy and ABT-888- Phase 1/randomized Phase 2 Study in |J. de Souza |
| | |Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck| |
|e. |N1153 |Phase I/II Study of Sorafenib + TH-302 in 1st line Advanced Hepatocellular |M. Borad |
| | |Carcinoma (HCC) and 2nd line Renal Cell Carcinoma (RCC) | |
|f. |N0871 |A Phase II Study of Carboplatin, Paclitaxel, and RAD001 in previously untreated |M. Goetz |
| | |Patients with Measurable Disease with Cancer of Unknown Primary (CUP) | |
|g. |N0879 |A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or |R. McWilliams |
| | |without Everolimus for Therapy of Metastatic Malignant Melanoma | |
|h. |N0185 |A Phase I/Feasibility Study of RAD001 plus R-CHOP for New Untreated Aggressive |P. Johnston |
| | |Lymphoma | |
|i. |A091201 |Randomized Phase II study comparing the MET Inhibitor XL184 to DTIC in Uveal |J. Luke |
| | |Melanoma | |
2. Status update on current trials in development: (appx. 40 min) Schwartz or Horvath
|a. |A091105 |Phase 3 double blind randomized placebo controlled trial of Sorafenib in Desmoid |M. Gounder |
| | |Tumors | |
|b. |A091302 |Randomized Phase II study of Sorafenib with or without Everolimus in Patients with|E. Sherman |
| | |Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer | |
|c. | A091305 |A Phase 2 Double-Blind Randomized Study of Efatutazone, an Oral PPAR Agonist, in |R. Smallridge |
| | |Combination with Paclitaxel versus Paclitaxel Plus Placebo in Patients with | |
| | |Advanced Anaplastic Thyroid Cancer | |
|d. | A091303 | A Randomized Double-Blinded Phase 3 Study of Palbociclib (PD0332991) in |M. Dickson |
| | |Well-differentiated / De-differentiated Liposarcoma | |
|e. |A091202 |A Phase II Randomized Study of the Peroxisome Proliferator-Activated Receptor |M. Pishvaian (GW) |
| | |Gamma Agonist, CS-7017 (Efatutazone) vs. Placebo in Patients with Previously | |
| | |Treated, Unresectable Myxoid Liposarcoma | |
3. Status of Concepts: (appx. 20 min) Erlichman
|a. |Randomized Phase 2 study of chemo and androgen ablation in salivary gland cancer EORTC 1206 |Ho (MSK) |
|b. |A Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced Sarcoma |W. Tap |
4. New Concepts (appx. 40 min) Schwartz/Erlichman
|a. |Treatment of Melanoma |J. Luke |
5. Central Office updates: Accrual committee, International Committee, Grant results - Horvath (appx 20min)
-----------------------
Charles Erlichman, MD, FRCPC, FACP
Co-Director for Experimental Therapeutics Committee
Mayo Clinic
200 First Street SW
Rochester, MN 55905
Phone: 507-266-3200
Email: Erlichman.charles@mayo.edu
Gary Schwartz, MD
Co-Director for Experimental Therapeutics Committee
Memorial Sloan-Kettering Cancer Center
300 East 66th St
New York, NY 10065
Phone: 646-888-4158 Email: schwartg@
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
Related searches
- stages of cancer and what they mean
- cancer and crp test
- cancer and low blood pressure
- cancer and high blood pressure
- cancer and high c reactive protein levels
- breast cancer and lymphedema
- bladder cancer and immunotherapy
- bladder cancer and radiation therapy
- group b hemolytic strep treatment
- uti group b strep treatment
- group b beta strep treatment
- group b strep in urine culture